|
| | | | | | | | | | | | |
MALLINCKRODT PLC |
CONDENSED CONSOLIDATED STATEMENTS OF INCOME |
Nine Months Ended June 26, 2015 |
(unaudited, in millions, except per share data) |
| | | | |
| GAAP Historical As Reported | Reclass to Discontinued Operations | Effect of Ongoing Supply Agreement (1) | Adjusted |
Net sales | $ | 2,741.3 |
| $ | (312.1 | ) | $ | 35.3 |
| $ | 2,464.5 |
|
Cost of sales | 1,280.6 |
| (222.9 | ) | 35.3 |
| 1,093.0 |
|
Gross profit | 1,460.7 |
| (89.2 | ) | — |
| 1,371.5 |
|
Selling, general and administrative expenses | 938.7 |
| (71.8 | ) | — |
| 866.9 |
|
Research and development expenses | 134.4 |
| (3.2 | ) | — |
| 131.2 |
|
Restructuring charges, net | 34.0 |
| (0.6 | ) | — |
| 33.4 |
|
Gains on divestiture and license | (2.6 | ) | — |
| — |
| (2.6 | ) |
Operating income | 356.2 |
| (13.6 | ) | — |
| 342.6 |
|
Interest expense | (178.7 | ) | — |
| — |
| (178.7 | ) |
Interest income | 0.7 |
| — |
| — |
| 0.7 |
|
Other income (expense), net | 7.7 |
| 0.3 |
| — |
| 8.0 |
|
Income from continuing operations before income taxes | 185.9 |
| (13.3 | ) | — |
| 172.6 |
|
Income tax (benefit) | (40.2 | ) | (5.4 | ) | — |
| (45.6 | ) |
Income from continuing operations | 226.1 |
| (7.9 | ) | — |
| 218.2 |
|
Income from discontinued operations, net of income taxes | 23.4 |
| 7.9 |
| — |
| 31.3 |
|
Net income | $ | 249.5 |
| $ | — |
| $ | — |
| $ | 249.5 |
|
| | | | |
Basic earnings per share: | | | | |
Income from continuing operations | $ | 1.94 |
| | | $ | 1.87 |
|
Income from discontinued operations | 0.20 |
| | | 0.27 |
|
Net income | 2.14 |
| | | 2.14 |
|
Diluted earnings per share: | | | | |
Income from continuing operations | $ | 1.91 |
| | | $ | 1.85 |
|
Income from discontinued operations | 0.20 |
| | | 0.26 |
|
Net income | 2.11 |
| | | 2.11 |
|
Weighted-average number of shares outstanding: | | | | |
Basic | 115.5 |
| | | 115.5 |
|
Diluted | 117.1 |
| | | 117.1 |
|
| | | | |
| | | | |
1.Represents historical CMDS-related intercompany transactions that will be Mallinckrodt continuing operations under an ongoing supply agreement with the acquirer of the CMDS business.
|
| | | | | | | | | | | | | |
MALLINCKRODT PLC |
NON-GAAP MEASURES |
Nine Months Ended June 26, 2015 |
(unaudited, in millions except per share data) |
| | | | | |
| Gross profit | Selling, general and administrative expenses | Income from continuing operations | | Diluted net income from continuing operations per share |
GAAP | $ | 1,460.7 |
| $ | 938.7 |
| $ | 226.1 |
| | $ | 1.91 |
|
Reclass to discontinued operations | (89.2 | ) | (71.8 | ) | (7.9 | ) | | (0.07 | ) |
Adjusted | 1,371.5 |
| 866.9 |
| 218.2 |
| | 1.85 |
|
Adjustments: | | | | | |
Intangible asset amortization | 392.4 |
| (4.3 | ) | 396.7 |
| | 3.39 |
|
Restructuring and related charges, net | — |
| — |
| 33.6 |
| | 0.29 |
|
Inventory step-up expense | 39.2 |
| — |
| 39.2 |
| | 0.33 |
|
Incremental equity conversion costs | — |
| (65.0 | ) | 65.0 |
| | 0.56 |
|
Acquisition related expenses | — |
| (30.6 | ) | 30.6 |
| | 0.26 |
|
Significant legal and environmental charges | — |
| (66.8 | ) | 66.8 |
| | 0.57 |
|
Income taxes (1) | — |
| — |
| (197.9 | ) | | (1.69 | ) |
Dilutive share impact (2) | — |
| — |
| (5.9 | ) | | (0.03 | ) |
As adjusted | $ | 1,803.1 |
| $ | 700.2 |
| $ | 646.3 |
| | $ | 5.52 |
|
| | | | | |
Percent of net sales | 73.2 | % | 28.4 | % | 26.2 | % | | |
| | | | | |
| | | | | |
1.Includes tax effect of above adjustments and U.S. tax payments associated with installment sale transactions.
2.For the nine months ended June 26, 2015, the diluted net income per share on a GAAP basis is presented on a dilutive basis using the two-class method of calculating net income per share. This method required that $1.9 million of net income from continuing operations to be allocated to participating securities for the nine months ended June 26, 2015. This adjustment reflects this allocation and a similar allocation of the above adjustments. Using the two-class method, the weighted-average number of shares were 117.1 million for the nine months ended June 26, 2015.
|
| | | | | | | | | | | | |
SEGMENT NET SALES |
Nine Months Ended June 26, 2015 |
(unaudited, in millions) |
| | | | |
| GAAP Historical As Reported | Reclass to Discontinued Operations | Effect of Ongoing Supply Agreement | Adjusted |
Specialty Brands | $ | 1,154.1 |
| $ | — |
| $ | — |
| $ | 1,154.1 |
|
Specialty Generics | 954.9 |
| — |
| — |
| 954.9 |
|
Global Medical Imaging | 603.5 |
| (283.3 | ) | — |
| 320.2 |
|
| 2,712.5 |
| (283.3 | ) | — |
| 2,429.2 |
|
Other(1) | 28.8 |
| (28.8 | ) | 35.3 |
| 35.3 |
|
Net sales | $ | 2,741.3 |
| $ | (312.1 | ) | $ | 35.3 |
| $ | 2,464.5 |
|
| | | | |
| | | | |
1.Historical reported amounts represent CMDS-related transactions with our former parent. Net sales from the ongoing supply agreement represent historical CMDS-related intercompany transactions that will be continuing operations under an ongoing supply agreement with the acquirer of the CMDS business.
|
| | | | | | | | | | | | |
MALLINCKRODT PLC |
CONDENSED CONSOLIDATED STATEMENTS OF INCOME |
Three Months Ended June 26, 2015 |
(unaudited, in millions, except per share data) |
| | | | |
| GAAP Historical As Reported | Reclass to Discontinued Operations | Effect of Ongoing Supply Agreement (1) | Adjusted |
Net sales | $ | 965.1 |
| $ | (102.2 | ) | $ | 14.4 |
| $ | 877.3 |
|
Cost of sales | 431.6 |
| (72.5 | ) | 14.4 |
| 373.5 |
|
Gross profit | 533.5 |
| (29.7 | ) | — |
| 503.8 |
|
Selling, general and administrative expenses | 332.7 |
| (21.8 | ) | — |
| 310.9 |
|
Research and development expenses | 45.0 |
| (1.0 | ) | — |
| 44.0 |
|
Restructuring charges, net | 23.1 |
| (0.4 | ) | — |
| 22.7 |
|
Gains on divestiture and license | (0.9 | ) | — |
| — |
| (0.9 | ) |
Operating income | 133.6 |
| (6.5 | ) | — |
| 127.1 |
|
Interest expense | (72.5 | ) | — |
| — |
| (72.5 | ) |
Interest income | 0.2 |
| — |
| — |
| 0.2 |
|
Other income (expense), net | (0.5 | ) | 0.1 |
| — |
| (0.4 | ) |
Income from continuing operations before income taxes | 60.8 |
| (6.4 | ) | — |
| 54.4 |
|
Income tax expense (benefit) | 3.3 |
| (4.5 | ) | — |
| (1.2 | ) |
Income from continuing operations | 57.5 |
| (1.9 | ) | — |
| 55.6 |
|
Income from discontinued operations, net of income taxes | 0.5 |
| 1.9 |
| — |
| 2.4 |
|
Net income | $ | 58.0 |
| $ | — |
| $ | — |
| $ | 58.0 |
|
| | | | |
Basic earnings per share: | | | | |
Income from continuing operations | $ | 0.49 |
| | | $ | 0.47 |
|
Income from discontinued operations | — |
| | | 0.02 |
|
Net income | 0.50 |
| | | 0.50 |
|
Diluted earnings per share: | | | | |
Income from continuing operations | $ | 0.48 |
| | | $ | 0.47 |
|
Income from discontinued operations | — |
| | | 0.02 |
|
Net income | 0.49 |
| | | 0.49 |
|
Weighted-average number of shares outstanding: | | | | |
Basic | 116.3 |
| | | 116.3 |
|
Diluted | 117.8 |
| | | 117.8 |
|
| | | | |
| | | | |
1.Represents historical CMDS-related intercompany transactions that will be Mallinckrodt continuing operations under an ongoing supply agreement with the acquirer of the CMDS business.
|
| | | | | | | | | | | | | |
MALLINCKRODT PLC |
NON-GAAP MEASURES |
Three Months Ended June 26, 2015 |
(unaudited, in millions except per share data) |
| | | | | |
| Gross profit | Selling, general and administrative expenses | Income from continuing operations | | Diluted net income from continuing operations per share |
GAAP | $ | 533.5 |
| $ | 332.7 |
| $ | 57.5 |
| | $ | 0.48 |
|
Reclass to discontinued operations | (29.7 | ) | (21.8 | ) | (1.9 | ) | | (0.02 | ) |
Adjusted | 503.8 |
| 310.9 |
| 55.6 |
| | 0.47 |
|
Adjustments: | | | | | |
Intangible asset amortization | 147.1 |
| (1.9 | ) | 149.0 |
| | 1.26 |
|
Restructuring and related charges, net | — |
| — |
| 22.7 |
| | 0.19 |
|
Inventory step-up expense | 4.0 |
| — |
| 4.0 |
| | 0.03 |
|
Incremental equity conversion costs | — |
| (19.6 | ) | 19.6 |
| | 0.17 |
|
Acquisition related expenses | — |
| (23.5 | ) | 23.5 |
| | 0.20 |
|
Significant legal and environmental charges | — |
| (15.5 | ) | 15.5 |
| | 0.13 |
|
Income taxes (1) | — |
| — |
| (49.6 | ) | | (0.42 | ) |
Dilutive share impact (2) | — |
| — |
| (1.8 | ) | | (0.01 | ) |
As adjusted | $ | 654.9 |
| $ | 250.4 |
| $ | 238.5 |
| | $ | 2.02 |
|
| | | | | |
Percent of net sales | 74.6 | % | 28.5 | % | 27.2 | % | | |
| | | | | |
| | | | | |
1.Includes tax effect of above adjustments and U.S. tax payments associated with installment sale transactions.
2.For the three months ended June 26, 2015, the diluted net income per share on a GAAP basis is presented on a dilutive basis using the two-class method of calculating net income per share. This method required $0.4 million of net income from continuing operations to be allocated to participating securities for the three months ended June 26, 2015. This adjustment reflects this allocation and a similar allocation of the above adjustments. Using the two-class method, the weighted-average number of shares were 117.8 million for the three months ended June 26, 2015.
|
| | | | | | | | | | | | |
SEGMENT NET SALES |
Three Months Ended June 26, 2015 |
(unaudited, in millions) |
| | | | |
| GAAP Historical As Reported | Reclass to Discontinued Operations | Effect of Ongoing Supply Agreement | Adjusted |
Specialty Brands | $ | 446.2 |
| $ | — |
| $ | — |
| $ | 446.2 |
|
Specialty Generics | 307.9 |
| — |
| — |
| 307.9 |
|
Global Medical Imaging | 201.6 |
| (92.8 | ) | — |
| 108.8 |
|
| 955.7 |
| (92.8 | ) | — |
| 862.9 |
|
Other(1) | 9.4 |
| (9.4 | ) | 14.4 |
| 14.4 |
|
Net sales | $ | 965.1 |
| $ | (102.2 | ) | $ | 14.4 |
| $ | 877.3 |
|
| | | | |
| | | | |
1.Historical reported amounts represent CMDS-related transactions with our former parent. Net sales from the ongoing supply agreement represent historical CMDS-related intercompany transactions that will be continuing operations under an ongoing supply agreement with the acquirer of the CMDS business.
|
| | | | | | | | | | | | |
MALLINCKRODT PLC |
CONDENSED CONSOLIDATED STATEMENTS OF INCOME |
Three Months Ended March 27, 2015 |
(unaudited, in millions, except per share data) |
| | | | |
| GAAP Historical As Reported | Reclass to Discontinued Operations | Effect of Ongoing Supply Agreement (1) | Adjusted |
Net sales | $ | 909.9 |
| $ | (103.3 | ) | $ | 12.4 |
| $ | 819.0 |
|
Cost of sales | 421.4 |
| (77.7 | ) | 12.4 |
| 356.1 |
|
Gross profit | 488.5 |
| (25.6 | ) | — |
| 462.9 |
|
Selling, general and administrative expenses | 343.5 |
| (22.8 | ) | — |
| 320.7 |
|
Research and development expenses | 47.0 |
| (1.3 | ) | — |
| 45.7 |
|
Restructuring charges, net | 3.7 |
| (0.2 | ) | — |
| 3.5 |
|
Gains on divestiture and license | (0.9 | ) | — |
| — |
| (0.9 | ) |
Operating income | 95.2 |
| (1.3 | ) | — |
| 93.9 |
|
Interest expense | (57.4 | ) | — |
| — |
| (57.4 | ) |
Interest income | 0.4 |
| — |
| — |
| 0.4 |
|
Other income (expense), net | 4.1 |
| 0.1 |
| — |
| 4.2 |
|
Income from continuing operations before income taxes | 42.3 |
| (1.2 | ) | — |
| 41.1 |
|
Income tax (benefit) | (34.2 | ) | 0.1 |
| — |
| (34.1 | ) |
Income from continuing operations | 76.5 |
| (1.3 | ) | — |
| 75.2 |
|
Income from discontinued operations, net of income taxes | 22.3 |
| 1.3 |
| — |
| 23.6 |
|
Net income | $ | 98.8 |
| $ | — |
| $ | — |
| $ | 98.8 |
|
| | | | |
Basic earnings per share: | | | | |
Income from continuing operations | $ | 0.66 |
| | | $ | 0.64 |
|
Income from discontinued operations | 0.19 |
| | | 0.20 |
|
Net income | 0.85 |
| | | 0.85 |
|
Diluted earnings per share: | | | | |
Income from continuing operations | $ | 0.65 |
| | | $ | 0.64 |
|
Income from discontinued operations | 0.19 |
| | | 0.20 |
|
Net income | 0.84 |
| | | 0.84 |
|
Weighted-average number of shares outstanding: | | | | |
Basic | 115.6 |
| | | 115.6 |
|
Diluted | 117.2 |
| | | 117.2 |
|
| | | | |
| | | | |
1.Represents historical CMDS-related intercompany transactions that will be Mallinckrodt continuing operations under an ongoing supply agreement with the acquirer of the CMDS business.
|
| | | | | | | | | | | | | |
MALLINCKRODT PLC |
NON-GAAP MEASURES |
Three Months Ended March 27, 2015 |
(unaudited, in millions except per share data) |
| | | | | |
| Gross profit | Selling, general and administrative expenses | Income from continuing operations | | Diluted net income from continuing operations per share |
GAAP | $ | 488.5 |
| $ | 343.5 |
| $ | 76.5 |
| | $ | 0.65 |
|
Reclass to discontinued operations | (25.6 | ) | (22.8 | ) | (1.3 | ) | | (0.01 | ) |
Adjusted | 462.9 |
| 320.7 |
| 75.2 |
| | 0.64 |
|
Adjustments: | | | | | |
Intangible asset amortization | 121.8 |
| (1.1 | ) | 122.9 |
| | 1.05 |
|
Restructuring and related charges, net | — |
| — |
| 3.6 |
| | 0.03 |
|
Inventory step-up expense | 4.4 |
| — |
| 4.4 |
| | 0.04 |
|
Incremental equity conversion costs | — |
| (21.6 | ) | 21.6 |
| | 0.18 |
|
Acquisition related expenses | — |
| (7.1 | ) | 7.1 |
| | 0.06 |
|
Significant legal and environmental charges | — |
| (51.3 | ) | 51.3 |
| | 0.44 |
|
Income taxes (1) | — |
| — |
| (85.2 | ) | | (0.73 | ) |
Dilutive share impact (2) | — |
| — |
| (1.8 | ) | | (0.01 | ) |
As adjusted | $ | 589.1 |
| $ | 239.6 |
| $ | 199.1 |
| | $ | 1.70 |
|
| | | | | |
Percent of net sales | 71.9 | % | 29.3 | % | 24.3 | % | | |
| | | | | |
| | | | | |
1.Includes tax effect of above adjustments and U.S. tax payments associated with installment sale transactions.
2.For the three months ended March 27, 2015, the diluted net income per share on a GAAP basis is presented on a dilutive basis using the two-class method of calculating net income per share. This method required $0.7 million of net income from continuing operations to be allocated to participating securities for the three months ended March 27, 2015. This adjustment reflects this allocation and a similar allocation of the above adjustments. Using the two-class method, the weighted-average number of shares were 117.2 million for the three months ended March 27, 2015.
|
| | | | | | | | | | | | |
SEGMENT NET SALES |
Three Months Ended March 27, 2015 |
(unaudited, in millions) |
| | | | |
| GAAP Historical As Reported | Reclass to Discontinued Operations | Effect of Ongoing Supply Agreement | Adjusted |
Specialty Brands | $ | 334.3 |
| $ | — |
| $ | — |
| $ | 334.3 |
|
Specialty Generics | 362.8 |
| — |
| — |
| 362.8 |
|
Global Medical Imaging | 202.6 |
| (93.1 | ) | — |
| 109.5 |
|
| 899.7 |
| (93.1 | ) | — |
| 806.6 |
|
Other(1) | 10.2 |
| (10.2 | ) | 12.4 |
| 12.4 |
|
Net sales | $ | 909.9 |
| $ | (103.3 | ) | $ | 12.4 |
| $ | 819.0 |
|
| | | | |
| | | | |
1.Historical reported amounts represent CMDS-related transactions with our former parent. Net sales from the ongoing supply agreement represent historical CMDS-related intercompany transactions that will be continuing operations under an ongoing supply agreement with the acquirer of the CMDS business.
|
| | | | | | | | | | | | |
MALLINCKRODT PLC |
CONDENSED CONSOLIDATED STATEMENTS OF INCOME |
Three Months Ended December 26, 2014 |
(unaudited, in millions, except per share data) |
| | | | |
| GAAP Historical As Reported | Reclass to Discontinued Operations | Effect of Ongoing Supply Agreement (1) | Adjusted |
Net sales | $ | 866.3 |
| $ | (106.6 | ) | $ | 8.5 |
| $ | 768.2 |
|
Cost of sales | 427.6 |
| (72.7 | ) | 8.5 |
| 363.4 |
|
Gross profit | 438.7 |
| (33.9 | ) | — |
| 404.8 |
|
Selling, general and administrative expenses | 262.5 |
| (27.2 | ) | — |
| 235.3 |
|
Research and development expenses | 42.4 |
| (0.9 | ) | — |
| 41.5 |
|
Restructuring charges, net | 7.2 |
| — |
| — |
| 7.2 |
|
Gains on divestiture and license | (0.8 | ) | — |
| — |
| (0.8 | ) |
Operating income | 127.4 |
| (5.8 | ) | — |
| 121.6 |
|
Interest expense | (48.8 | ) | — |
| — |
| (48.8 | ) |
Interest income | 0.1 |
| — |
| — |
| 0.1 |
|
Other income (expense), net | 4.1 |
| 0.1 |
| — |
| 4.2 |
|
Income from continuing operations before income taxes | 82.8 |
| (5.7 | ) | — |
| 77.1 |
|
Income tax (benefit) | (9.3 | ) | (1.0 | ) | — |
| (10.3 | ) |
Income from continuing operations | 92.1 |
| (4.7 | ) | — |
| 87.4 |
|
Income from discontinued operations, net of income taxes | 0.6 |
| 4.7 |
| — |
| 5.3 |
|
Net income | $ | 92.7 |
| $ | — |
| $ | — |
| $ | 92.7 |
|
| | | | |
Basic earnings per share: | | | | |
Income from continuing operations | $ | 0.79 |
| | | $ | 0.75 |
|
Income from discontinued operations | 0.01 |
| | | 0.05 |
|
Net income | 0.80 |
| | | 0.80 |
|
Diluted earnings per share: | | | | |
Income from continuing operations | $ | 0.78 |
| | | $ | 0.74 |
|
Income from discontinued operations | 0.01 |
| | | 0.05 |
|
Net income | 0.79 |
| | | 0.79 |
|
Weighted-average number of shares outstanding: | | | | |
Basic | 114.8 |
| | | 114.8 |
|
Diluted | 116.3 |
| | | 116.3 |
|
| | | | |
| | | | |
1.Represents historical CMDS-related intercompany transactions that will be Mallinckrodt continuing operations under an ongoing supply agreement with the acquirer of the CMDS business.
|
| | | | | | | | | | | | | |
MALLINCKRODT PLC |
NON-GAAP MEASURES |
Three Months Ended December 26, 2014 |
(unaudited, in millions except per share data) |
| | | | | |
| Gross profit | Selling, general and administrative expenses | Income from continuing operations | | Diluted net income from continuing operations per share |
GAAP | $ | 438.7 |
| $ | 262.5 |
| $ | 92.1 |
| | $ | 0.78 |
|
Reclass to discontinued operations | (33.9 | ) | (27.2 | ) | (4.7 | ) | | (0.03 | ) |
Adjusted | 404.8 |
| 235.3 |
| 87.4 |
| | 0.74 |
|
Adjustments: | | | | | |
Intangible asset amortization | 123.5 |
| (1.3 | ) | 124.8 |
| | 1.07 |
|
Restructuring and related charges, net | — |
| — |
| 7.3 |
| | 0.06 |
|
Inventory step-up expense | 30.8 |
| — |
| 30.8 |
| | 0.26 |
|
Incremental equity conversion costs | — |
| (23.8 | ) | 23.8 |
| | 0.20 |
|
Income taxes (1) | — |
| — |
| (63.1 | ) | | (0.54 | ) |
Dilutive share impact (2) | — |
| — |
| (2.3 | ) | | (0.01 | ) |
As adjusted | $ | 559.1 |
| $ | 210.2 |
| $ | 208.7 |
| | $ | 1.79 |
|
| | | | | |
Percent of net sales | 72.8 | % | 27.4 | % | 27.2 | % | | |
| | | | | |
| | | | | |
1.Includes tax effect of above adjustments and U.S. tax payments associated with installment sale transactions.
2.For the three months ended December 26, 2014, the diluted net income per share on a GAAP basis is presented on a dilutive basis using the two-class method of calculating net income per share. This method required that $0.9 million of net income from continuing operations to be allocated to participating securities for the three months ended December 26, 2014. This adjustment reflects this allocation and a similar allocation of the above adjustments. Using the two-class method, the weighted-average number of shares were 116.3 million for the three months ended December 26, 2014.
|
| | | | | | | | | | | | |
SEGMENT NET SALES |
Three Months Ended December 26, 2014 |
(unaudited, in millions) |
| | | | |
| GAAP Historical As Reported | Reclass to Discontinued Operations | Effect of Ongoing Supply Agreement | Adjusted |
Specialty Brands | $ | 373.6 |
| $ | — |
| $ | — |
| $ | 373.6 |
|
Specialty Generics | 284.2 |
| — |
| — |
| 284.2 |
|
Global Medical Imaging | 199.3 |
| (97.4 | ) | — |
| 101.9 |
|
| 857.1 |
| (97.4 | ) | — |
| 759.7 |
|
Other(1) | 9.2 |
| (9.2 | ) | 8.5 |
| 8.5 |
|
Net sales | $ | 866.3 |
| $ | (106.6 | ) | $ | 8.5 |
| $ | 768.2 |
|
| | | | |
| | | | |
1.Historical reported amounts represent CMDS-related transactions with our former parent. Net sales from the ongoing supply agreement represent historical CMDS-related intercompany transactions that will be continuing operations under an ongoing supply agreement with the acquirer of the CMDS business.
|
| | | | | | | | | | | | |
MALLINCKRODT PLC |
CONDENSED CONSOLIDATED STATEMENTS OF INCOME |
Fiscal Year Ended September 26, 2014 |
(unaudited, in millions, except per share data) |
| | | | |
| GAAP Historical As Reported | Reclass to Discontinued Operations | Effect of Ongoing Supply Agreement (1) | Adjusted |
Net sales | $ | 2,540.4 |
| $ | (495.8 | ) | $ | 37.4 |
| $ | 2,082.0 |
|
Cost of sales | 1,337.3 |
| (352.9 | ) | 37.4 |
| 1,021.8 |
|
Gross profit | 1,203.1 |
| (142.9 | ) | — |
| 1,060.2 |
|
Selling, general and administrative expenses | 842.1 |
| (97.1 | ) | — |
| 745.0 |
|
Research and development expenses | 166.9 |
| (3.4 | ) | — |
| 163.5 |
|
Restructuring charges, net | 128.6 |
| (47.2 | ) | — |
| 81.4 |
|
Non-restructuring impairment charges | 355.6 |
| (204.0 | ) | — |
| 151.6 |
|
Separation costs | 9.6 |
| — |
| — |
| 9.6 |
|
Gains on divestiture and license | (15.6 | ) | 0.6 |
| — |
| (15.0 | ) |
Operating (loss) | (284.1 | ) | 208.2 |
| — |
| (75.9 | ) |
Interest expense | (82.6 | ) | — |
| — |
| (82.6 | ) |
Interest income | 1.5 |
| — |
| — |
| 1.5 |
|
Other income (expense), net | 1.8 |
| 1.3 |
| — |
| 3.1 |
|
Loss from continuing operations before income taxes | (363.4 | ) | 209.5 |
| — |
| (153.9 | ) |
Income tax (benefit) | (44.8 | ) | 34.7 |
| | (10.1 | ) |
Loss from continuing operations | (318.6 | ) | 174.8 |
| — |
| (143.8 | ) |
Loss from discontinued operations, net of income taxes | (0.7 | ) | (174.8 | ) | — |
| (175.5 | ) |
Net loss | $ | (319.3 | ) | $ | — |
| $ | — |
| $ | (319.3 | ) |
| | | | |
Basic earnings per share: | | | | |
Loss from continuing operations | $ | (4.91 | ) | | | $ | (2.22 | ) |
Loss from discontinued operations | (0.01 | ) | | | (2.70 | ) |
Net loss | (4.92 | ) | | | (4.92 | ) |
Diluted earnings per share: | | | | |
Loss from continuing operations | $ | (4.91 | ) | | | $ | (2.22 | ) |
Loss from discontinued operations | (0.01 | ) | | | (2.70 | ) |
Net loss | (4.92 | ) | | | (4.92 | ) |
Weighted-average number of shares outstanding: | | | | |
Basic | 64.9 |
| | | 64.9 |
|
Diluted | 64.9 |
| | | 64.9 |
|
| | | | |
| | | | |
1.Represents historical CMDS-related intercompany transactions that will be Mallinckrodt continuing operations under an ongoing supply agreement with the acquirer of the CMDS business.
|
| | | | | | | | | | | | | |
MALLINCKRODT PLC |
NON-GAAP MEASURES |
Fiscal Year Ended September 26, 2014 |
(unaudited, in millions except per share data) |
| | | | | |
| | | | | |
| Gross profit | Selling, general and administrative expenses | Income (loss) from continuing operations | | Diluted net income from continuing operations per share |
GAAP | $ | 1,203.1 |
| $ | 842.1 |
| $ | (318.6 | ) | | $ | (4.91 | ) |
Reclass to discontinued operations | (142.9 | ) | (97.1 | ) | 174.8 |
| | 2.69 |
|
Adjusted | 1,060.2 |
| 745.0 |
| (143.8 | ) | | (2.22 | ) |
Adjustments: | | | | | |
Intangible asset amortization | 153.8 |
| (1.0 | ) | 154.8 |
| | 2.36 |
|
Restructuring and related charges, net | — |
| — |
| 81.9 |
| | 1.25 |
|
Non-restructuring impairment | — |
| — |
| 151.6 |
| | 2.31 |
|
Inventory step-up expense | 25.7 |
| — |
| 25.7 |
| | 0.39 |
|
Incremental equity conversion costs | — |
| (13.0 | ) | 13.0 |
| | 0.20 |
|
Separation costs | — |
| — |
| 9.6 |
| | 0.15 |
|
Up-front and milestone payments (1) | — |
| — |
| 5.0 |
| | 0.08 |
|
Acquisition related expenses | — |
| (65.1 | ) | 65.1 |
| | 0.99 |
|
Significant legal and environmental charges | (14.3 | ) | (49.6 | ) | 35.3 |
| | 0.54 |
|
Gain on intellectual property license | — |
| — |
| (11.7 | ) | | (0.18 | ) |
Income taxes (2) | — |
| — |
| (94.2 | ) | | (1.43 | ) |
Dilutive share impact (3) | — |
| — |
| (0.8 | ) | | (0.01 | ) |
As adjusted | $ | 1,225.4 |
| $ | 616.3 |
| $ | 291.5 |
| | $ | 4.44 |
|
| | | | | |
Percent of net sales | 58.9 | % | 29.6 | % | 14.0 | % | | |
| | | | | |
| | | | | |
1.As charge related to a milestone payment prior to regulatory approval this amount is included within research & development expenses.
2.Includes tax effect of above adjustments and certain effects associated with acquisitions.
3.For fiscal 2014, the diluted net income per share on a GAAP basis and diluted net income per share impacts of each adjustment are calculated using 64.9 million shares, which assumes no dilution from outstanding equity awards as they would have been antidilutive on a GAAP basis. The non-GAAP adjusted diluted net income per share is presented on a dilutive basis using the two-class method of calculating net income per share. Using the two-class method the weighted-average number of shares was 65.7 million.
|
| | | | | | | | | | | | |
MALLINCKRODT PLC |
SEGMENT NET SALES |
Fiscal Year Ended September 26, 2014 |
(unaudited, in millions) |
| | | | |
| GAAP Historical As Reported | Reclass to Discontinued Operations | Effect of Ongoing Supply Agreement | Adjusted |
Specialty Brands | $ | 413.5 |
| $ | — |
| $ | — |
| $ | 413.5 |
|
Specialty Generics | 1,199.4 |
| — |
| — |
| 1,199.4 |
|
Global Medical Imaging | 881.5 |
| (449.8 | ) | — |
| 431.7 |
|
| 2,494.4 |
| (449.8 | ) | — |
| 2,044.6 |
|
Other(1) | 46.0 |
| (46.0 | ) | 37.4 |
| 37.4 |
|
Net sales | $ | 2,540.4 |
| $ | (495.8 | ) | $ | 37.4 |
| $ | 2,082.0 |
|
| | | | |
| | | | |
1.Historical reported amounts represent CMDS-related transactions with our former parent. Net sales from the ongoing supply agreement represent historical CMDS-related intercompany transactions that will be continuing operations under an ongoing supply agreement with the acquirer of the CMDS business.
|
| | | | | | | | | | | | |
MALLINCKRODT PLC |
CONDENSED CONSOLIDATED STATEMENTS OF INCOME |
Three Months Ended September 26, 2014 |
(unaudited, in millions, except per share data) |
| | | | |
| GAAP Historical As Reported | Reclass to Discontinued Operations | Effect of Ongoing Supply Agreement (1) | Adjusted |
Net sales | $ | 789.3 |
| $ | (120.0 | ) | $ | 4.4 |
| $ | 673.7 |
|
Cost of sales | 388.7 |
| (82.6 | ) | 4.4 |
| 310.5 |
|
Gross profit | 400.6 |
| (37.4 | ) | — |
| 363.2 |
|
Selling, general and administrative expenses | 280.5 |
| (28.8 | ) | — |
| 251.7 |
|
Research and development expenses | 43.8 |
| 1.2 |
| — |
| 45.0 |
|
Restructuring charges, net | 75.1 |
| (21.2 | ) | — |
| 53.9 |
|
Non-restructuring impairment charges | 355.6 |
| (204.0 | ) | — |
| 151.6 |
|
Separation costs | 3.0 |
| — |
| — |
| 3.0 |
|
Gains on divestiture and license | (0.9 | ) | 0.1 |
| — |
| (0.8 | ) |
Operating loss | (356.5 | ) | 215.3 |
| — |
| (141.2 | ) |
Interest expense | (37.7 | ) | — |
| — |
| (37.7 | ) |
Interest income | 0.4 |
| — |
| — |
| 0.4 |
|
Other income (expense), net | 2.7 |
| 0.3 |
| — |
| 3.0 |
|
Loss from continuing operations before income taxes | (391.1 | ) | 215.6 |
| — |
| (175.5 | ) |
Income tax (benefit) | (38.7 | ) | 36.7 |
| — |
| (2.0 | ) |
Loss from continuing operations | (352.4 | ) | 178.9 |
| — |
| (173.5 | ) |
Loss from discontinued operations, net of income taxes | — |
| (178.9 | ) | — |
| (178.9 | ) |
Net loss | $ | (352.4 | ) | $ | — |
| $ | — |
| $ | (352.4 | ) |
| | | | |
Basic earnings per share: | | | | |
Loss from continuing operations | $ | (4.14 | ) | | | $ | (2.04 | ) |
Loss from discontinued operations | — |
| | | (2.10 | ) |
Net loss | (4.14 | ) | | | (4.14 | ) |
Diluted earnings per share: | | | | |
Loss from continuing operations | $ | (4.14 | ) | | | $ | (2.04 | ) |
Loss from discontinued operations | — |
| | | (2.10 | ) |
Net loss | (4.14 | ) | | | (4.14 | ) |
Weighted-average number of shares outstanding: | | | | |
Basic | 85.2 |
| | | 85.2 |
|
Diluted | 85.2 |
| | | 85.2 |
|
| | | | |
| | | | |
1.Represents historical CMDS-related intercompany transactions that will be Mallinckrodt continuing operations under an ongoing supply agreement with the acquirer of the CMDS business.
|
| | | | | | | | | | | | | |
MALLINCKRODT PLC |
NON-GAAP MEASURES |
Three Months Ended September 26, 2014 |
(unaudited, in millions except per share data) |
| | | | | |
| | | | | |
| Gross profit | Selling, general and administrative expenses | Income (loss) from continuing operations | | Diluted net income from continuing operations per share |
GAAP | $ | 400.6 |
| $ | 280.5 |
| $ | (352.4 | ) | | $ | (4.14 | ) |
Reclass to discontinued operations | (37.4 | ) | (28.8 | ) | 178.9 |
| | 2.10 |
|
Adjusted | 363.2 |
| 251.7 |
| (173.5 | ) | | (2.04 | ) |
Adjustments: | | | | | |
Intangible asset amortization | 83.7 |
| (0.8 | ) | 84.5 |
| | 0.98 |
|
Restructuring and related charges, net | — |
| — |
| 53.8 |
| | 0.62 |
|
Non-restructuring impairment charges | — |
| — |
| 151.6 |
| | 1.75 |
|
Inventory step-up expense | 15.1 |
| — |
| 15.1 |
| | 0.17 |
|
Incremental equity conversion costs | — |
| (13.0 | ) | 13.0 |
| | 0.15 |
|
Separation costs | — |
| — |
| 3.0 |
| | 0.03 |
|
Acquisition related expenses | — |
| (30.0 | ) | 30.0 |
| | 0.35 |
|
Significant legal and environmental charges | (14.3 | ) | (15.0 | ) | 0.7 |
| | 0.01 |
|
Income taxes (1) | — |
| — |
| (40.0 | ) | | (0.46 | ) |
Dilutive share impact (2) | | | (1.2 | ) | | (0.01 | ) |
As adjusted | $ | 447.7 |
| $ | 192.9 |
| $ | 137.0 |
| | $ | 1.59 |
|
| | | | | |
Percent of net sales | 66.5 | % | 28.6 | % | 20.3 | % | | |
| | | | | |
| | | | | |
1.Includes tax effect of above adjustments and certain effects associated with acquisitions.
2.For the three months ended September 26, 2014, the diluted net income per share on a GAAP basis and diluted net income per share impacts of each adjustment are calculated using 85.2 million shares, which assumes no dilution from outstanding equity awards as they would have been antidilutive on a GAAP basis. The non-GAAP adjusted diluted net income per share is presented on a dilutive basis using the two-class method of calculating net income per share. Using the two-class method the weighted-average number of shares was 86.4 million
|
| | | | | | | | | | | | |
MALLINCKRODT PLC |
SEGMENT NET SALES |
Three Months Ended September 26, 2014 |
(unaudited, in millions) |
| | | | |
| GAAP Historical As Reported | Reclass to Discontinued Operations | Effect of Ongoing Supply Agreement | Adjusted |
Specialty Brands | $ | 213.9 |
| $ | — |
| $ | — |
| $ | 213.9 |
|
Specialty Generics | 350.9 |
| — |
| — |
| 350.9 |
|
Global Medical Imaging | 213.4 |
| (108.9 | ) | — |
| 104.5 |
|
| 778.2 |
| (108.9 | ) | — |
| 669.3 |
|
Other(1) | 11.1 |
| (11.1 | ) | 4.4 |
| 4.4 |
|
Net sales | $ | 789.3 |
| $ | (120.0 | ) | $ | 4.4 |
| $ | 673.7 |
|
| | | | |
| | | | |
1.Historical reported amounts represent CMDS-related transactions with our former parent. Net sales from the ongoing supply agreement represent historical CMDS-related intercompany transactions that will be continuing operations under an ongoing supply agreement with the acquirer of the CMDS business.
|
| | | | | | | | | | | | |
MALLINCKRODT PLC |
CONDENSED CONSOLIDATED STATEMENTS OF INCOME |
Three Months Ended June 27, 2014 |
(unaudited, in millions, except per share data) |
| | | | |
| GAAP Historical As Reported | Reclass to Discontinued Operations | Effect of Ongoing Supply Agreement (1) | Adjusted |
Net sales | $ | 653.1 |
| $ | (128.4 | ) | $ | 5.4 |
| $ | 530.1 |
|
Cost of sales | 368.8 |
| (98.2 | ) | 5.4 |
| 276.0 |
|
Gross profit | 284.3 |
| (30.2 | ) | — |
| 254.1 |
|
Selling, general and administrative expenses | 221.3 |
| (20.0 | ) | — |
| 201.3 |
|
Research and development expenses | 42.7 |
| (1.7 | ) | — |
| 41.0 |
|
Restructuring charges, net | 23.8 |
| (1.9 | ) | — |
| 21.9 |
|
Separation costs | 1.8 |
| — |
| — |
| 1.8 |
|
Gains on divestiture and license | (0.9 | ) | 0.3 |
| — |
| (0.6 | ) |
Operating loss | (4.4 | ) | (6.9 | ) | — |
| (11.3 | ) |
Interest expense | (22.7 | ) | — |
| — |
| (22.7 | ) |
Interest income | 0.3 |
| — |
| — |
| 0.3 |
|
Other income (expense), net | 0.1 |
| 0.3 |
| — |
| 0.4 |
|
Loss from continuing operations before income taxes | (26.7 | ) | (6.6 | ) | — |
| (33.3 | ) |
Income tax (benefit) | (2.4 | ) | (1.9 | ) | — |
| (4.3 | ) |
Loss from continuing operations | (24.3 | ) | (4.7 | ) | — |
| (29.0 | ) |
Income from discontinued operations, net of income taxes | 0.2 |
| 4.7 |
| — |
| 4.9 |
|
Net loss | $ | (24.1 | ) | $ | — |
| $ | — |
| $ | (24.1 | ) |
| | | | |
Basic earnings per share: | | | | |
Loss from continuing operations | $ | (0.42 | ) | | | $ | (0.50 | ) |
Income from discontinued operations | — |
| | | 0.08 |
|
Net loss | (0.41 | ) | | | (0.41 | ) |
Diluted earnings per share: | | | | |
Loss from continuing operations | $ | (0.42 | ) | | | $ | (0.50 | ) |
Income from discontinued operations | — |
| | | 0.08 |
|
Net loss | (0.41 | ) | | | (0.41 | ) |
Weighted-average number of shares outstanding: | | | | |
Basic | 58.5 |
| | | 58.5 |
|
Diluted | 58.5 |
| | | 58.5 |
|
| | | | |
| | | | |
1.Represents historical CMDS-related intercompany transactions that will be Mallinckrodt continuing operations under an ongoing supply agreement with the acquirer of the CMDS business.
|
| | | | | | | | | | | | | |
MALLINCKRODT PLC |
NON-GAAP MEASURES |
Three Months Ended June 27, 2014 |
(unaudited, in millions except per share data) |
| | | | | |
| Gross profit | Selling, general and administrative expenses | Income (loss) from continuing operations | | Diluted net income from continuing operations per share |
GAAP | $ | 284.3 |
| $ | 221.3 |
| $ | (24.3 | ) | | $ | (0.42 | ) |
Reclass to discontinued operations | (30.2 | ) | (20.0 | ) | (4.7 | ) | | (0.08 | ) |
Adjusted | 254.1 |
| 201.3 |
| (29.0 | ) | | (0.50 | ) |
Adjustments: | | | | | |
Intangible asset amortization | 49.7 |
| (0.1 | ) | 49.8 |
| | 0.84 |
|
Restructuring and related charges, net | — |
| — |
| 22.3 |
| | 0.37 |
|
Inventory step-up expense | 9.5 |
| — |
| 9.5 |
| | 0.16 |
|
Separation costs | — |
| — |
| 1.8 |
| | 0.03 |
|
Up-front and milestone payments (1) | — |
| — |
| 5.0 |
| | 0.08 |
|
Acquisition related expenses | — |
| (16.6 | ) | 16.6 |
| | 0.28 |
|
Significant legal and environmental charges | — |
| (11.5 | ) | 11.5 |
| | 0.19 |
|
Income taxes (2) | — |
| — |
| (22.8 | ) | | (0.38 | ) |
As adjusted (3) | $ | 313.3 |
| $ | 173.1 |
| $ | 64.7 |
| | $ | 1.09 |
|
| | | | | |
Percent of net sales | 59.1 | % | 32.7 | % | 12.2 | % | | |
| | | | | |
| | | | | |
1.As charge related to a milestone payment prior to regulatory approval this amount is included within research & development expenses.
2.Includes tax effect of above adjustments and certain effects associated with acquisitions.
3.For the three months ended June 27, 2014 the weighted-average number of shares reflects 59.5 million shares as compared to 58.5 million shares used in determining diluted earnings per share prepared in accordance with GAAP. The above non-GAAP measure includes 1.0 million shares that would be antidilutive to GAAP diluted earnings per share.
|
| | | | | | | | | | | | |
SEGMENT NET SALES |
Three Months Ended June 26, 2014 |
(unaudited, in millions) |
| | | | |
| GAAP Historical As Reported | Reclass to Discontinued Operations | Effect of Ongoing Supply Agreement | Adjusted |
Specialty Brands | $ | 84.9 |
| $ | — |
| $ | — |
| $ | 84.9 |
|
Specialty Generics | 329.4 |
| — |
| — |
| 329.4 |
|
Global Medical Imaging | 227.1 |
| (116.7 | ) | — |
| 110.4 |
|
| 641.4 |
| (116.7 | ) | — |
| 524.7 |
|
Other(1) | 11.7 |
| (11.7 | ) | 5.4 |
| 5.4 |
|
Net sales | $ | 653.1 |
| $ | (128.4 | ) | $ | 5.4 |
| $ | 530.1 |
|
| | | | |
| | | | |
1.Historical reported amounts represent CMDS-related transactions with our former parent. Net sales from the ongoing supply agreement represent historical CMDS-related intercompany transactions that will be continuing operations under an ongoing supply agreement with the acquirer of the CMDS business.
|
| | | | | | | | | | | | |
MALLINCKRODT PLC |
CONDENSED CONSOLIDATED STATEMENTS OF INCOME |
Three Months Ended March 28, 2014 |
(unaudited, in millions, except per share data) |
| | | | |
| GAAP Historical As Reported | Reclass to Discontinued Operations | Effect of Ongoing Supply Agreement (1) | Adjusted |
Net sales | $ | 557.8 |
| $ | (123.7 | ) | $ | 14.6 |
| $ | 448.7 |
|
Cost of sales | 295.2 |
| (87.8 | ) | 14.6 |
| 222.0 |
|
Gross profit | 262.6 |
| (35.9 | ) | — |
| 226.7 |
|
Selling, general and administrative expenses | 194.1 |
| (21.6 | ) | — |
| 172.5 |
|
Research and development expenses | 41.4 |
| (1.4 | ) | — |
| 40.0 |
|
Restructuring charges, net | 21.7 |
| (24.0 | ) | — |
| (2.3 | ) |
Separation costs | 2.6 |
| — |
| — |
| 2.6 |
|
Gains on divestiture and license | (0.9 | ) | 0.1 |
| — |
| (0.8 | ) |
Operating income | 3.7 |
| 11.0 |
| — |
| 14.7 |
|
Interest expense | (12.4 | ) | — |
| — |
| (12.4 | ) |
Interest income | 0.5 |
| — |
| — |
| 0.5 |
|
Other income (expense), net | (0.4 | ) | 0.4 |
| — |
| — |
|
Income (loss) from continuing operations before income taxes | (8.6 | ) | 11.4 |
| — |
| 2.8 |
|
Income tax (benefit) | (20.3 | ) | 2.9 |
| — |
| (17.4 | ) |
Income from continuing operations | 11.7 |
| 8.5 |
| — |
| 20.2 |
|
Loss from discontinued operations, net of income taxes | (0.1 | ) | (8.5 | ) | — |
| (8.6 | ) |
Net income | $ | 11.6 |
| $ | — |
| $ | — |
| $ | 11.6 |
|
| | | | |
Basic earnings per share: | | | | |
Income from continuing operations | $ | 0.20 |
| | | $ | 0.35 |
|
Loss from discontinued operations | — |
| | | (0.15 | ) |
Net income | 0.20 |
| | | 0.20 |
|
Diluted earnings per share: | | | | |
Income from continuing operations | $ | 0.20 |
| | | $ | 0.34 |
|
Loss from discontinued operations | — |
| | | (0.15 | ) |
Net income | 0.20 |
| | | 0.20 |
|
Weighted-average number of shares outstanding: | | | | |
Basic | 58.2 |
| | | 58.2 |
|
Diluted | 59.1 |
| | | 59.1 |
|
| | | | |
| | | | |
1.Represents historical CMDS-related intercompany transactions that will be Mallinckrodt continuing operations under an ongoing supply agreement with the acquirer of the CMDS business.
|
| | | | | | | | | | | | | |
MALLINCKRODT PLC |
NON-GAAP MEASURES |
Three Months Ended March 28, 2014 |
(unaudited, in millions except per share data) |
| | | | | |
| | | | | |
| Gross profit | Selling, general and administrative expenses | Income from continuing operations | | Diluted net income from continuing operations per share |
GAAP | $ | 262.6 |
| $ | 194.1 |
| $ | 11.7 |
| | $ | 0.20 |
|
Reclass to discontinued operations | (35.9 | ) | (21.6 | ) | 8.5 |
| | 0.14 |
|
Adjusted | 226.7 |
| 172.5 |
| 20.2 |
| | 0.34 |
|
Adjustments: | | | | | |
Intangible asset amortization | 13.5 |
| (0.1 | ) | 13.6 |
| | 0.23 |
|
Restructuring and related charges, net | — |
| — |
| (2.3 | ) | | (0.04 | ) |
Inventory step-up expense | 1.1 |
| — |
| 1.1 |
| | 0.02 |
|
Separation costs | — |
| — |
| 2.6 |
| | 0.04 |
|
Acquisition related expenses | — |
| (18.5 | ) | 18.5 |
| | 0.31 |
|
Significant legal and environmental charges | — |
| (23.1 | ) | 23.1 |
| | 0.39 |
|
Income taxes (1) | — |
| — |
| (30.1 | ) | | (0.51 | ) |
As adjusted | $ | 241.3 |
| $ | 130.8 |
| $ | 46.7 |
| | $ | 0.79 |
|
| | | | | |
Percent of net sales | 53.8 | % | 29.2 | % | 10.4 | % | | |
| | | | | |
| | | | | |
1.Includes tax effect of above adjustments and certain effects associated with acquisitions.
|
| | | | | | | | | | | | |
SEGMENT NET SALES |
Three Months Ended March 28, 2014 |
(unaudited, in millions) |
| | | | |
| GAAP Historical As Reported | Reclass to Discontinued Operations | Effect of Ongoing Supply Agreement | Adjusted |
Specialty Brands | $ | 55.1 |
| $ | — |
| $ | — |
| $ | 55.1 |
|
Specialty Generics | 269.2 |
| — |
| — |
| 269.2 |
|
Global Medical Imaging | 222.4 |
| (112.6 | ) | — |
| 109.8 |
|
| 546.7 |
| (112.6 | ) | — |
| 434.1 |
|
Other(1) | 11.1 |
| (11.1 | ) | 14.6 |
| 14.6 |
|
Net sales | $ | 557.8 |
| $ | (123.7 | ) | $ | 14.6 |
| $ | 448.7 |
|
| | | | |
| | | | |
1.Historical reported amounts represent CMDS-related transactions with our former parent. Net sales from the ongoing supply agreement represent historical CMDS-related intercompany transactions that will be continuing operations under an ongoing supply agreement with the acquirer of the CMDS business.
|
| | | | | | | | | | | | |
MALLINCKRODT PLC |
CONDENSED CONSOLIDATED STATEMENTS OF INCOME |
Three Months Ended December 27, 2013 |
(unaudited, in millions, except per share data) |
| | | | |
| GAAP Historical As Reported | Reclass to Discontinued Operations | Effect of Ongoing Supply Agreement (1) | Adjusted |
Net sales | $ | 540.2 |
| $ | (123.7 | ) | $ | 13.0 |
| $ | 429.5 |
|
Cost of sales | 284.6 |
| (84.3 | ) | 13.0 |
| 213.3 |
|
Gross profit | 255.6 |
| (39.4 | ) | — |
| 216.2 |
|
Selling, general and administrative expenses | 146.2 |
| (26.7 | ) | — |
| 119.5 |
|
Research and development expenses | 39.0 |
| (1.5 | ) | — |
| 37.5 |
|
Restructuring charges, net | 8.0 |
| (0.1 | ) | — |
| 7.9 |
|
Separation costs | 2.2 |
| — |
| — |
| 2.2 |
|
Gains on divestiture and license | (12.9 | ) | 0.1 |
| — |
| (12.8 | ) |
Operating income | 73.1 |
| (11.2 | ) | — |
| 61.9 |
|
Interest expense | (9.8 | ) | — |
| — |
| (9.8 | ) |
Interest income | 0.3 |
| — |
| — |
| 0.3 |
|
Other income (expense), net | (0.6 | ) | 0.3 |
| — |
| (0.3 | ) |
Income from continuing operations before income taxes | 63.0 |
| (10.9 | ) | — |
| 52.1 |
|
Income tax expense | 16.6 |
| (3.0 | ) | — |
| 13.6 |
|
Income from continuing operations | 46.4 |
| (7.9 | ) | — |
| 38.5 |
|
Income (loss) from discontinued operations, net of income taxes | (0.8 | ) | 7.9 |
| — |
| 7.1 |
|
Net income | $ | 45.6 |
| $ | — |
| $ | — |
| $ | 45.6 |
|
| | | | |
Basic earnings per share: | | | | |
Income from continuing operations | $ | 0.80 |
| | | $ | 0.67 |
|
Income (loss) from discontinued operations | (0.01 | ) | | | 0.12 |
|
Net income | 0.79 |
| | | 0.79 |
|
Diluted earnings per share: | | | | |
Income from continuing operations | $ | 0.79 |
| | | $ | 0.66 |
|
Income (loss) from discontinued operations | (0.01 | ) | | | 0.12 |
|
Net income | 0.78 |
| | | 0.78 |
|
Weighted-average number of shares outstanding: | | | | |
Basic | 57.8 |
| | | 57.8 |
|
Diluted | 58.4 |
| | | 58.4 |
|
| | | | |
| | | | |
1.Represents historical CMDS-related intercompany transactions that will be Mallinckrodt continuing operations under an ongoing supply agreement with the acquirer of the CMDS business.
|
| | | | | | | | | | | | | |
MALLINCKRODT PLC |
NON-GAAP MEASURES |
Three Months Ended December 27, 2013 |
(unaudited, in millions except per share data) |
| | | | | |
| | | | | |
| Gross profit | Selling, general and administrative expenses | Income from continuing operations | | Diluted net income from continuing operations per share |
GAAP | $ | 255.6 |
| $ | 146.2 |
| $ | 46.4 |
| | $ | 0.79 |
|
Reclass to discontinued operations | (39.4 | ) | (26.7 | ) | (7.9 | ) | | (0.14 | ) |
Adjusted | 216.2 |
| 119.5 |
| 38.5 |
| | 0.66 |
|
Adjustments: | | | | | |
Intangible asset amortization | 6.9 |
| — |
| 6.9 |
| | 0.12 |
|
Restructuring and related charges, net | — |
| — |
| 8.0 |
| | 0.14 |
|
Separation costs | — |
| — |
| 2.2 |
| | 0.04 |
|
Gain on intellectual property license | — |
| — |
| (11.7 | ) | | (0.20 | ) |
Income taxes | — |
| — |
| (1.3 | ) | | (0.02 | ) |
As adjusted | $ | 223.1 |
| $ | 119.5 |
| $ | 42.6 |
| | $ | 0.73 |
|
| | | | | |
Percent of net sales | 51.9 | % | 27.8 | % | 9.9 | % | | |
| | | | | |
| | | | | |
|
| | | | | | | | | | | | |
SEGMENT NET SALES |
Three Months Ended December 26, 2013 |
(unaudited, in millions) |
| | | | |
| GAAP Historical As Reported | Reclass to Discontinued Operations | Effect of Ongoing Supply Agreement | Adjusted |
Specialty Brands | $ | 59.6 |
| $ | — |
| $ | — |
| $ | 59.6 |
|
Specialty Generics | 249.9 |
| — |
| — |
| 249.9 |
|
Global Medical Imaging | 218.6 |
| (111.6 | ) | — |
| 107.0 |
|
| 528.1 |
| (111.6 | ) | — |
| 416.5 |
|
Other(1) | 12.1 |
| (12.1 | ) | 13.0 |
| 13.0 |
|
Net sales | $ | 540.2 |
| $ | (123.7 | ) | $ | 13.0 |
| $ | 429.5 |
|
| | | | |
| | | | |
1.Historical reported amounts represent CMDS-related transactions with our former parent. Net sales from the ongoing supply agreement represent historical CMDS-related intercompany transactions that will be continuing operations under an ongoing supply agreement with the acquirer of the CMDS business.
|
| | | | | | | | | | | | |
MALLINCKRODT PLC |
CONDENSED CONSOLIDATED STATEMENTS OF INCOME |
Fiscal Year Ended September 27, 2013 |
(unaudited, in millions, except per share data) |
| | | | |
| GAAP Historical As Reported | Reclass to Discontinued Operations | Effect of Ongoing Supply Agreement (1) | Adjusted |
Net sales | $ | 2,204.5 |
| $ | (549.3 | ) | $ | 57.1 |
| $ | 1,712.3 |
|
Cost of sales | 1,179.6 |
| (346.7 | ) | 57.1 |
| 890.0 |
|
Gross profit | 1,024.9 |
| (202.6 | ) | — |
| 822.3 |
|
Selling, general and administrative expenses | 609.9 |
| (114.0 | ) | — |
| 495.9 |
|
Research and development expenses | 165.7 |
| (7.8 | ) | — |
| 157.9 |
|
Restructuring charges, net | 33.2 |
| (9.5 | ) | — |
| 23.7 |
|
Separation costs | 74.2 |
| — |
| — |
| 74.2 |
|
Gains on divestiture and license | (2.9 | ) | — |
| — |
| (2.9 | ) |
Operating income | 144.8 |
| (71.3 | ) | — |
| 73.5 |
|
Interest expense | (19.5 | ) | — |
| — |
| (19.5 | ) |
Interest income | 0.3 |
| — |
| — |
| 0.3 |
|
Other income (expense), net | 0.8 |
| 0.6 |
| — |
| 1.4 |
|
Income from continuing operations before income taxes | 126.4 |
| (70.7 | ) | — |
| 55.7 |
|
Income tax expense | 68.6 |
| (21.1 | ) | | 47.5 |
|
Income from continuing operations | 57.8 |
| (49.6 | ) | — |
| 8.2 |
|
Income from discontinued operations, net of income taxes | 1.0 |
| 49.6 |
| — |
| 50.6 |
|
Net income | $ | 58.8 |
| $ | — |
| $ | — |
| $ | 58.8 |
|
| | | | |
Basic earnings per share: | | | | |
Income (loss) from continuing operations | $ | 1.00 |
| | | $ | 0.14 |
|
Income from discontinued operations | 0.02 |
| | | 0.88 |
|
Net income | 1.02 |
| | | 1.02 |
|
Diluted earnings per share: | | | | |
Income (loss) from continuing operations | $ | 1.00 |
| | | $ | 0.14 |
|
Income from discontinued operations | 0.02 |
| | | 0.88 |
|
Net income | 1.02 |
| | | 1.02 |
|
Weighted-average number of shares outstanding: | | | | |
Basic | 57.7 |
| | | 57.7 |
|
Diluted | 57.8 |
| | | 57.8 |
|
| | | | |
| | | | |
1.Represents historical CMDS-related intercompany transactions that will be Mallinckrodt continuing operations under an ongoing supply agreement with the acquirer of the CMDS business.
|
| | | | | | | | | | | | | |
MALLINCKRODT PLC |
NON-GAAP MEASURES |
Fiscal Year Ended September 27, 2013 |
(unaudited, in millions except per share data) |
| | | | | |
| | | | | |
| Gross profit | Selling, general and administrative expenses | Income from continuing operations | | Diluted net income from continuing operations per share |
GAAP | $ | 1,024.9 |
| $ | 609.9 |
| $ | 57.8 |
| | $ | 1.00 |
|
Reclass to discontinued operations | (202.6 | ) | (114.0 | ) | (49.6 | ) | | (0.86 | ) |
Adjusted | 822.3 |
| 495.9 |
| 8.2 |
| | 0.14 |
|
Adjustments: | | | | | |
Intangible asset amortization | 27.9 |
| — |
| 27.9 |
| | 0.48 |
|
Restructuring and related charges, net | — |
| — |
| 26.3 |
| | 0.46 |
|
Separation costs | — |
| — |
| 74.2 |
| | 1.28 |
|
Up-front and milestone payments (1) | — |
| — |
| 5.0 |
| | 0.09 |
|
Income taxes | — |
| — |
| (21.3 | ) | | (0.37 | ) |
As adjusted | $ | 850.2 |
| $ | 495.9 |
| $ | 120.3 |
| | $ | 2.08 |
|
| | | | | |
Percent of net sales | 49.7 | % | 29.0 | % | 7.0 | % | | |
| | | | | |
| | | | | |
1.As charge related to a milestone payment prior to regulatory approval this amount is included within research & development expenses.
|
| | | | | | | | | | | | |
SEGMENT NET SALES |
Fiscal Year Ended September 27, 2013 |
(unaudited, in millions) |
| | | | |
| GAAP Historical As Reported | Reclass to Discontinued Operations | Effect of Ongoing Supply Agreement | Adjusted |
Specialty Brands | $ | 206.4 |
| $ | — |
| $ | — |
| $ | 206.4 |
|
Specialty Generics | 1,011.2 |
| — |
| — |
| 1,011.2 |
|
Global Medical Imaging | 935.7 |
| (498.1 | ) | — |
| 437.6 |
|
| 2,153.3 |
| (498.1 | ) | — |
| 1,655.2 |
|
Other(1) | 51.2 |
| (51.2 | ) | 57.1 |
| 57.1 |
|
Net sales | $ | 2,204.5 |
| $ | (549.3 | ) | $ | 57.1 |
| $ | 1,712.3 |
|
| | | | |
| | | | |
1.Historical reported amounts represent CMDS-related transactions with our former parent. Net sales from the ongoing supply agreement represent historical CMDS-related intercompany transactions that will be continuing operations under an ongoing supply agreement with the acquirer of the CMDS business.
|
| | | | | | | | | | | | |
MALLINCKRODT PLC |
CONDENSED CONSOLIDATED STATEMENTS OF INCOME |
Fiscal Year Ended September 28, 2012 |
(unaudited, in millions, except per share data) |
| | | | |
| GAAP Historical As Reported | Reclass to Discontinued Operations | Effect of Ongoing Supply Agreement (1) | Adjusted |
Net sales | $ | 2,056.2 |
| $ | (596.2 | ) | $ | 73.0 |
| $ | 1,533.0 |
|
Cost of sales | 1,091.4 |
| (350.3 | ) | 73.0 |
| 814.1 |
|
Gross profit | 964.8 |
| (245.9 | ) | — |
| 718.9 |
|
Selling, general and administrative expenses | 551.7 |
| (128.5 | ) | — |
| 423.2 |
|
Research and development expenses | 144.1 |
| (5.7 | ) | — |
| 138.4 |
|
Restructuring charges, net | 11.2 |
| 0.7 |
| — |
| 11.9 |
|
Separation costs | 25.5 |
| — |
| — |
| 25.5 |
|
Gains on divestiture and license | (2.9 | ) | — |
| — |
| (2.9 | ) |
Operating income | 235.2 |
| (112.4 | ) | — |
| 122.8 |
|
Interest expense | (0.5 | ) | — |
| — |
| (0.5 | ) |
Interest income | 0.4 |
| — |
| — |
| 0.4 |
|
Other income (expense), net | 1.0 |
| — |
| — |
| 1.0 |
|
Income from continuing operations before income taxes | 236.1 |
| (112.4 | ) | — |
| 123.7 |
|
Income tax expense | 94.8 |
| (29.6 | ) | — |
| 65.2 |
|
Income from continuing operations | 141.3 |
| (82.8 | ) | — |
| 58.5 |
|
Income (loss) from discontinued operations, net of income taxes | (6.7 | ) | 82.8 |
| — |
| 76.1 |
|
Net income | $ | 134.6 |
| $ | — |
| $ | — |
| $ | 134.6 |
|
| | | | |
Basic earnings per share: | | | | |
Income from continuing operations | $ | 2.45 |
| | | $ | 1.01 |
|
Income (loss) from discontinued operations | (0.12 | ) | | | 1.32 |
|
Net income | 2.33 |
| | | 2.33 |
|
Diluted earnings per share: | | | | |
Income from continuing operations | $ | 2.45 |
| | | $ | 1.01 |
|
Income (loss) from discontinued operations | (0.12 | ) | | | 1.32 |
|
Net income | 2.33 |
| | | 2.33 |
|
Weighted-average number of shares outstanding: | | | | |
Basic | 57.7 |
| | | 57.7 |
|
Diluted | 57.7 |
| | | 57.7 |
|
| | | | |
| | | | |
1.Represents historical CMDS-related intercompany transactions that will be Mallinckrodt continuing operations under an ongoing supply agreement with the acquirer of the CMDS business.
|
| | | | | | | | | | | | | |
MALLINCKRODT PLC |
NON-GAAP MEASURES |
Fiscal Year Ended September 28, 2012 |
(unaudited, in millions except per share data) |
| | | | | |
| | | | | |
| Gross profit | Selling, general and administrative expenses | Income from continuing operations | | Diluted net income from continuing operations per share |
GAAP | $ | 964.8 |
| $ | 551.7 |
| $ | 141.3 |
| | $ | 2.45 |
|
Reclass to discontinued operations | (245.9 | ) | (128.5 | ) | (82.8 | ) | | (1.44 | ) |
Adjusted | 718.9 |
| 423.2 |
| 58.5 |
| | 1.01 |
|
Adjustments: | | | | | |
Intangible asset amortization | 19.8 |
| — |
| 19.8 |
| | 0.34 |
|
Restructuring and related charges, net | — |
| — |
| 19.9 |
| | 0.34 |
|
Separation costs | — |
| — |
| 25.5 |
| | 0.44 |
|
Income taxes | — |
| — |
| (14.4 | ) | | (0.25 | ) |
As adjusted | $ | 738.7 |
| $ | 423.2 |
| $ | 109.3 |
| | $ | 1.89 |
|
| | | | | |
Percent of net sales | 48.2 | % | 27.6 | % | 7.1 | % | | |
| | | | | |
| | | | | |
|
| | | | | | | | | | | | |
SEGMENT NET SALES AND OPERATIONAL GROWTH |
Fiscal Year Ended September 28, 2012 |
(unaudited, in millions) |
| | | | |
| GAAP Historical As Reported | Reclass to Discontinued Operations | Effect of Ongoing Supply Agreement | Adjusted |
Specialty Brands | $ | 156.4 |
| $ | — |
| $ | — |
| $ | 156.4 |
|
Specialty Generics | 848.8 |
| — |
| — |
| 848.8 |
|
Global Medical Imaging | 996.8 |
| (542.0 | ) | — |
| 454.8 |
|
| 2,002.0 |
| (542.0 | ) | — |
| 1,460.0 |
|
Other(1) | 54.2 |
| (54.2 | ) | 73.0 |
| 73.0 |
|
Net sales | $ | 2,056.2 |
| $ | (596.2 | ) | $ | 73.0 |
| $ | 1,533.0 |
|
| | | | |
| | | | |
1.Historical reported amounts represent CMDS-related transactions with our former parent. Net sales from the ongoing supply agreement represent historical CMDS-related intercompany transactions that will be continuing operations under an ongoing supply agreement with the acquirer of the CMDS business.